Links Thera P, Verbeek Hans H G, Hofstra Robert M W, Plukker John Th M
Department of EndocrinologyUniversity Medical Centre Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The NetherlandsDepartment of GeneticsErasmus Medical Centre, Rotterdam, The NetherlandsDepartment of Surgical OncologyUniversity Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Eur J Endocrinol. 2015 Jun;172(6):R241-51. doi: 10.1530/EJE-14-0726. Epub 2015 Jan 27.
The treatment for metastasised medullary thyroid cancer is still a topic of discussion. One of the main challenges remains to find effective adjuvant and palliative options for patients with metastatic disease. The diagnostic and treatment strategies for this tumour are discussed and possible new developments commented. Approaches that target rearranged during transfection (RET) are preferable to those that target RET downstream proteins as, theoretically, blocking RET downstream targets will block only one of the many pathways activated by RET. Combining several agents would seem to be more promising, in particular agents that target RET with those that independently target RET signalling pathways or the more general mechanism of tumour progression.
转移性甲状腺髓样癌的治疗仍是一个讨论的话题。主要挑战之一仍然是为转移性疾病患者找到有效的辅助和姑息治疗方案。本文讨论了该肿瘤的诊断和治疗策略,并对可能的新进展进行了评论。靶向转染重排(RET)的方法优于靶向RET下游蛋白的方法,因为从理论上讲,阻断RET下游靶点只会阻断由RET激活的众多途径之一。联合使用几种药物似乎更有前景,特别是将靶向RET的药物与独立靶向RET信号通路或更普遍的肿瘤进展机制的药物联合使用。